Acurx Pharmaceuticals Files S-1 Registration
Ticker: ACXP · Form: S-1 · Filed: May 21, 2025 · CIK: 1736243
Sentiment: neutral
Topics: s-1, ipo, pharmaceuticals, sec-filing
TL;DR
Acurx Pharma just filed an S-1, get ready for a potential public offering!
AI Summary
Acurx Pharmaceuticals, Inc. filed an S-1 registration statement with the SEC on May 21, 2025. The company, incorporated in Delaware, is seeking to register securities under the Securities Act of 1933. Its principal executive offices are located at 259 Liberty Avenue, Staten Island, New York. David P. Luci serves as the President and Chief Executive Officer.
Why It Matters
This S-1 filing indicates Acurx Pharmaceuticals is preparing to offer its securities to the public, which could lead to significant capital infusion for its operations and potential growth.
Risk Assessment
Risk Level: medium — As an S-1 filing, it signifies a company seeking to go public or raise capital, which inherently carries risks associated with market volatility and the success of the offering.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
- 82-3733567 — EIN (IRS Employer Identification Number)
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- May 21, 2025 (date) — Filing Date
- 259 Liberty Avenue, Staten Island, New York 10305 (address) — Principal Executive Offices
- David P. Luci (person) — President and Chief Executive Officer
- 333-287478 (registration_number) — SEC File Number
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement under the Securities Act of 1933, indicating Acurx Pharmaceuticals, Inc. is preparing to offer its securities to the public.
When was this S-1 filing submitted to the SEC?
The S-1 filing was submitted to the Securities and Exchange Commission on May 21, 2025.
Who is the President and CEO of Acurx Pharmaceuticals, Inc.?
David P. Luci is the President and Chief Executive Officer of Acurx Pharmaceuticals, Inc.
What is the primary business classification for Acurx Pharmaceuticals, Inc.?
The primary Standard Industrial Classification (SIC) Code Number for Acurx Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Where are Acurx Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices of Acurx Pharmaceuticals, Inc. are located at 259 Liberty Avenue, Staten Island, New York 10305.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on May 21, 2025 by David P. Luci regarding Acurx Pharmaceuticals, Inc. (ACXP).